• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Samsung Bioepis Gets FDA Approval for Biosimilar of J&J’s Stelara

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 01, 2024 at 10:12: PM
via Samsung Bioepis announced Monday that the FDA has approved Pyzchiva (ustekinumab—ttwe), a biosimilar of Johnson & Johnson’s blockbuster immunotherapy Stelara.

article source
 

<



Similar threads

cafead
Samsung Bioepis, J&amp;J Ink Settlement and License Deal for Stelara Biosimilar
Replies
0
Views
136
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&amp;J’s Stelara
Replies
0
Views
163
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports
Replies
0
Views
91
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen, Samsung Bioepis launch ranibizumab-nuna in US
Replies
0
Views
146
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biogen to sell stake in Samsung Bioepis JV for up to $2.3bn
Replies
0
Views
154
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote